The company is developing topical and systemic therapies based on Liver X Receptor (LXR) modulators. The initial focus for the company is on the clinical development of ALX-101, a topical LXR-based therapy, for the treatment of various cutaneous inflammatory disorders, including atopic dermatitis.
May 31, 2017
Ralexar Therapeutics Initiates Phase 2b Study of ALX-101 in Patients with Atopic Dermatitis
Mar 30, 2016
640 Lee Road, Ste 118,
Wayne, PA 19087
P: 267.465.7565
Email: dpfeiffer@ralexar.com
Legal and Copyright Disclaimer | Privacy Policy
© 2021 Ralexar Therapeutics.
All Rights Reserved.
Web Design & Development time4design - Bucks County Web Design.